opc 28326 has been researched along with talipexole in 1 studies
Studies (opc 28326) | Trials (opc 28326) | Recent Studies (post-2010) (opc 28326) | Studies (talipexole) | Trials (talipexole) | Recent Studies (post-2010) (talipexole) |
---|---|---|---|---|---|
9 | 1 | 1 | 426 | 2 | 12 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hashimoto, A; Imaizumi, T; Kambe, T; Kishi, M; Mori, T; Nakazawa, T; Orito, K | 1 |
1 other study(ies) available for opc 28326 and talipexole
Article | Year |
---|---|
alpha(2)-adrenoceptor antagonist properties of OPC-28326, a novel selective peripheral vasodilator.
Topics: Adrenergic alpha-Antagonists; Aniline Compounds; Animals; Azepines; Binding, Competitive; Blood Pressure; Brimonidine Tartrate; Decerebrate State; Dose-Response Relationship, Drug; In Vitro Techniques; Male; Muscle Contraction; Mydriasis; Piperidines; Quinoxalines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Synaptic Transmission; Vas Deferens; Vasodilator Agents; Yohimbine | 2001 |